■ Glaukos Corporation achieved 36% net sales growth to $58.6 million in the second quarter of 2019, higher than its $43.2 million in sales in the second quarter of 2018. The company also updated its 2019 net sales guidance to $226 million to $231 million, whereas previously it was $225 million to $230 million.

“We are very pleased with the company’s record second quarter financial performance, along with the significant clinical and regulatory progress we continue to make to advance and expand our transformative pipeline,” said Thomas Burns, Glaukos president and CEO, in a news release. “We remain focused on execution as we build upon our solid foundation to transform Glaukos into a global ophthalmic pharmaceutical and device leader capable of providing novel treatment options for the benefit of patients worldwide.” GP